Plain-English translation of NCT02826486 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied whether , a new experimental drug, could work better when combined with (an immunotherapy that helps your immune system fight cancer) or with other drugs. Researchers tested the medication in patients with advanced pancreatic cancer that had spread to other parts of the body and could not be surgically removed.
Pancreatic cancer that has spread is very difficult to treat, and most current treatments don't work well enough. This trial was designed to see if this new medication approach could help patients live longer and have better outcomes than standard treatments alone.
Participants first received daily injections of the medication for five days, then moved into a longer treatment phase lasting up to two years. Depending on which group they were in, they received the medication either two or three times per week by injection, plus infusions every three weeks, and some participants also received additional drugs. Participants had regular clinic visits to monitor how well the treatment was working and check for side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States